Searchable abstracts of presentations at key conferences in endocrinology

ea0042p5 | (1) | Androgens2016

Androgen pathway regulating microRNAs in prostate cancer progression and therapy

Kalofonou Foteini , Fletcher Claire , Waxman Jonathan , Bevan Charlotte

Prostate cancer is an androgen dependent malignancy that initially responds well to androgen ablation therapy. However treatment, castrate resistant prostate cancer eventually emerges. Even in that phase of the disease, the androgen receptor (AR) still seems to play a role. MicroRNAs are small (19–25nt) non-coding RNAs that modulate gene silencing through inhibition of translation and mRNA degradation. They are considered to be master regulators of gene expression and act...

ea0081ep78 | Adrenal and Cardiovascular Endocrinology | ECE2022

Subthreshold cortisol deficiency-another ray in the spectrum?

Adamidou Foteini , Komzia Paraskevi , Kita Marina

Introduction: In Endocrinology, subclinical disorders meet certain diagnostic laboratory thresholds, but are by definition asymptomatic. Subthreshold disorders in Endocrinology have not been defined. We describe two cases of cortisol deficiency, primary and secondary, with normal baseline cortisol, which were by presentation clinical, but could be characterized as subthreshold by biochemical cut-off criteria.Case 1: A 47-year-old woman was referred for a...

ea0081ep402 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Bariatric Surgery in Type 1 Diabetes patients: a single centre study

Chopra Tanya , Wills Alice , Kavvoura Foteini

Background: Bariatric surgery significantly aids weight loss, improves glycaemic control and/or induces remission in Type 2 Diabetes patients. However, the impact of bariatric surgery in Type 1 diabetes (T1D) patients is less well-understood. With an increasing prevalence of obesity within the T1D population, it is important to identify whether bariatric surgery improves glycaemic control and prevents future complications.Aim: To evaluate the effect on B...

ea0081ep207 | Calcium and Bone | ECE2022

rhPTH(1-84) treatment-induced increased bone turnover in a young woman with postsurgical hypoparathyroidism

Adamidou Foteini , Komzia Paraskevi , Mintziori Gesthimani , Kita Marina

Introduction: rhPTH(1-84) replacement is the treatment of choice in adults with hypoparathyroidism not adequately controlled on standard therapy. Although increased bone turnover markers have consistently been reported in trials of safety and efficacy, marked elevations coupled with significant symptoms have been rare. We describe a case of increased treatment-induced bone turnover, necessitating significant therapeutic adjustments and monitoring.Case re...

ea0081ep795 | Pituitary and Neuroendocrinology | ECE2022

Response to classic dynamic tests of a corticotropinoma due to Nelson’s syndrome

Adamidou Foteini , Komzia Paraskevi , Divaris Efstathios , Panagiotou Athanasios , Kita Marina

Introduction: Nelson’s syndrome is a rare complication of Cushing’s disease treated with bilateral adrenalectomy. There is no effective medical treatment yet. Nelson’s patients respond to hypothalamic stimuli distinctly from patients with Cushing’s disease and those with Addison’s disease. We describe the responses to standard ACTH stimulation tests in a patient with Nelson’s syndrome.Case report: A 42-year-old woman present...

ea0090ep1162 | Late Breaking | ECE2023

Can we predict medical treatment failure in Graves’ disease? 4-year follow-up data in a single centre

Leonidas Liarakos Alexandros , Foka Anna , Mohamed Ahmed , Kavvoura Foteini

Background: Graves’ disease (GD) is the commonest cause of primary hyperthyroidism in iodine-sufficient areas. First-line treatment is a 12-18 month course of anti-thyroid drugs (ATD). However, around 50% of GD patients will relapse, requiring further assessment and definitive treatment with radioactive iodine or thyroidectomy. Identifying risk factors that predict relapse or treatment failure after stopping ATD is important in guiding management. Several risk factors hav...

ea0094p134 | Thyroid | SFEBES2023

Identifying risk factors that predict medical treatment failure in Graves’ disease: a 4-year follow-up study in a single centre

Liarakos Alexandros , Foka Anna , Mohamed Ahmed , Kavvoura Foteini

Background: Graves’ disease (GD) is the commonest cause of primary hyperthyroidism. First-line treatment involves 12-18 months of anti-thyroid drugs (ATD). Subsequently, around 50% of patients will relapse, requiring definitive treatment. Identifying risk factors that predict relapse or treatment failure can guide management. We aimed to explore risk factors that identify patients at high risk of relapse or medical treatment failure, to allow prioritisati...

ea0081p564 | Calcium and Bone | ECE2022

Quantification of cerebral calcification and nephrocalcinosis in patients with hypoparathyroidism

Adamidou Foteini , Chartampilas Evagelos , Komzia Paraskevi , Prassopoulos Panagiotis , Kita Marina , Papavramidis Theodosios S.

Introduction: Various methods to quantify calcified coronary plaque have been used in common clinical practice in the past few decades to compliment cardiovascular risk assessment. The estimation of calcium load in other organs and conditions has been at best semi-quantitative. Patients with long-standing hypoparathyroidism are known to suffer with nephrocalcinosis and basal ganglia calcification. We attempted to quantify end-organ calcium burden in a series of patients with v...

ea0081ep590 | Endocrine-Related Cancer | ECE2022

Pheochromocytomas and paragangliomas-real world data in a tertiary Greek center

Thanasoula Foteini , Angelousi Anna , Kyriakopoulos Georgios , Yavropoulou Maria , Kassi Evanthia , Kaltsas Gregory

Purpose: Pheochromocytomas (PCs) and paragangliomas (PGLs) are rare neuroendocrine tumors arising from chromaffin cells of the adrenal medulla and the sympathetic/parasympathetic neural ganglia, respectively. Metastatic PCs/PGLs occur in about 5-26% of cases. Their management and diagnosis still remain a challenge due to their heterogeneity, the absence of guidelines and the few prognostic tools.Aim: The aim of this study was to describe clinical and gen...

ea0063gp155 | Cushing's | ECE2019

Endocrine immune-related adverse events following immune checkpoint inhibitors in patients with advanced melanoma: single-center retrospective analysis

Kassi Eva , Angelousi Anna , Asonitis Nikos , Petychaki Foteini , Diamantopoulos Panayiotis , Anastasopoulou Amalia , Benopoulou Olga , Gogas Helen

Introduction: Immune-check point inhibitors (ICPis) has been shown to significantly improve survival in patients with advanced melanoma. Immune-related endocrinopathies (irEs) and in particular hypophysitis and thyroid dysfunction have been well described with an incidence varying from 9–17% and 3.8–13.2% respectively.Methods: This is a retrospective analysis of irEs in 325 (190 men) patients with melanoma receiving ICPis (PD-1/PDL-1 or CTLA-4 ...